

LIXISENATIDA

Bibliografía

Todas las referencias bibliográficas están tomadas del Informe de Evaluación CEVIME (www.osakidetza.euskadi.net/cevime/es).

1. Ficha técnica Lyxumia®. Sanofi-Aventis. Disponible en URL: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf
2. Comité de Medicamentos de Uso Humano (CHMP). Informe Público Europeo de Evaluación (EPAR). Lyxumia® (Lixisenatida). 28 November 2012; EMA/CHMP/703852/2012.
3. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). *Diabetes Care*. 2012;35(6):1225-31.
4. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M). *Diabetes Care*. 2013;36(9):2543-50.
5. Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*. 2013;36(9):2489-96.
6. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonyleurea (GetGoal-L-Asia). *Diabetes Obes Metab*. 2012 Oct;14(10):910-7.
7. Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, et al. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care*. 2013;36(10):2945-51.
8. Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). *Diabetes Obes Metab*. 2013 Nov;15(11):1000-7.
9. Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo1). *Diabetes Care*. 2013;36(9):2497-503.
10. NICE: Evidence summary: new medicine. ESNM26: Type 2 diabetes: lixisenatide. Published: 24 September 2013. Disponible en URL: <http://publications.nice.org.uk/esnm26type-2-diabetes-lixisenatide-esnm26>
11. SMC advice on Lixisenatide. Nº 903/13. August 2013. Disponible en URL: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/903_13_lixisenatide_Lyxumia/lixisenatide_Lyxumia
12. Canadian Agency for Drugs and Technologies in Health. Optimal use recommendations for second and third-line therapy for patients with type 2 diabetes. Ottawa: The Agency;2013.(CADTH optimal use report;vol.3,no1d). Disponible en URL: http://www.cadth.ca/media/pdf/OP0512_Diabetes_RecsReport_2nd_3rd-line_e.pdf
13. Aguilar Diosdado M, coordinador, et al. Proceso Asistencial Integrado Diabetes mellitus, 2ª ed. [Internet]. Sevilla: Consejería de Salud, 2011. Disponible en URL: http://www.juntadeandalucia.es/salud/export/sites/csadul/galerias/documentos/p_3_p_3_procesos_asistenciales_integrados/diabetes_mellitus/diabetes_mellitus.pdf
14. GCP sobre DM tipo 2 de Euskadi (en revisión).
15. National Institute of Health and Clinical Excellence. Clinical guideline 87. Type 2 diabetes: the management of type 2 diabetes. May 2009. Disponible en: <http://guidance.nice.org.uk/CG87/Guidance/pdf/English>.
16. Ficha Técnica BYETTA® (exenatida) Disponible en URL: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf